Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Corixa to file Melacine BLA for stage II melanoma

Sep. 29, 2000

Immunomedics commences phase III clinical trial with LymphoCide

Sep. 28, 2000

Vical reports interim data from phase II trial of Leuvectin

Sep. 26, 2000

ImmunoGen/SmithKline Beecham open second trial of cancer treatment

Sep. 26, 2000

Inhibition of NK cells by cancer cells from patients with CML prevented by Maxamine

Sep. 26, 2000

Biomira reports update of drug development programs

Sep. 25, 2000

Seattle Genetics initiates phase I trial of SGN-10 combination therapy

Sep. 21, 2000

Maxamine scheduled for December advisory panel review

Sep. 20, 2000

Cel-Sci receives grant for cervical cancer study with Multikine

Sep. 20, 2000

Phase I/II clinical trial demonstrates safety and tolerability of GVAX lung cancer vaccine

Sep. 15, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...